Clinical Trial 24384

• Overview

  Study Title:

  A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, an Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants with Relapsed or Refractory Multiple Myeloma

• Treatments

  Therapies:

  Anti-CD38 monoclonal antibody; Cell Therapy; Immunotherapy

  Medications:

  AZD4045 (); Aldesleukin (Interleukin-2); Daratumumab ()

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.